World Cancer Research Fund International

CUP Continuous Update Project

Analysing research on cancer prevention and survival

Diet, nutrition, physical activity and **kidney cancer**

2015

In partnership with

American Institute for Cancer Research

World Cancer Research Fund

Wereld Kanker Onderzoek Fonds

World Cancer Research Fund 世界癌症研究基金會

Contents

WORLD CANCER RESEARCH FUND INTERNATIONAL

OUR VISION

We want to live in a world where no one develops a preventable cancer.

OUR MISSION

We champion the latest and most authoritative scientific research from around the world on cancer prevention and survival through diet, weight and physical activity, so that we can help people make informed choices to reduce their cancer risk.

As a network, we influence policy at the highest level and are trusted advisors to governments and to other official bodies from around the world.

OUR NETWORK

World Cancer Research Fund International is a not-for-profit organisation that leads and unifies a network of cancer charities with a global reach, dedicated to the prevention of cancer through diet, weight and physical activity.

The World Cancer Research Fund network of charities is based in Europe, the Americas and Asia, giving us a global voice to inform people about cancer prevention.

OUR CONTINUOUS UPDATE PROJECT (CUP)

World Cancer Research Fund International's Continuous Update Project (CUP) analyses global cancer prevention and survival research linked to diet, nutrition, physical activity and weight. Among experts worldwide it is a trusted, authoritative scientific resource, which underpins current guidelines and policy for cancer prevention.

The CUP is produced in partnership with the American Institute for Cancer Research, World Cancer Research Fund UK, World Cancer Research Fund NL and World Cancer Research Fund HK.

The findings from the CUP are used to update our Recommendations for Cancer Prevention, which were originally published in *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective* (our Second Expert Report) [1]. These ensure that everyone – from policymakers and health professionals to members of the public – has access to the most up-to-date information on how to reduce the risk of developing the disease.

As part of the CUP, scientific research from around the world is collated and added to a database of epidemiological studies on an ongoing basis and systematically reviewed by a team at Imperial College London. An independent panel of world-renowned experts then evaluate and interpret the evidence to make conclusions based on the body of scientific evidence. Their conclusions form the basis for reviewing and, where necessary, revising our Recommendations for Cancer Prevention (see inside back cover).

A review of the Recommendations for Cancer Prevention is expected to be published in 2017, once an analysis of all of the cancers being assessed has been conducted. So far, new CUP reports have been published with updated evidence on breast, colorectal, pancreatic, endometrial, ovarian, prostate, liver and gallbladder cancers. In addition, our first CUP report on breast cancer survivors was published in October 2014.

This CUP report on kidney cancer updates the kidney cancer section of the Second Expert Report (section 7.15) and is based on the findings of the CUP Kidney Cancer Systematic Literature Review (SLR) and the CUP Expert Panel discussion in June 2014. For further details, please see the full CUP Kidney SLR 2015 **(wcrf.org/Kidney-Cancer-SLR-2015)**.

HOW TO CITE THIS REPORT

World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report: Diet, Nutrition, Physical Activity and Kidney Cancer. 2015. Available at: **wcrf.org/kidney-cancer-2015**

All CUP reports are available at wcrf.org/cupreports

[1] World Cancer Research Fund/American Institute for Cancer Research, *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective*. wcrf.org/int/research-we-fund/continuous-update-project-cup/second-expert-report. 2007.

EXECUTIVE SUMMARY

Background and context

Globally, the incidence rates of kidney cancer are predicted to increase. Currently, kidney cancer – also known as renal cancer – is the 12th most common cancer worldwide, with 337,860 cases recorded in 2012. However, the International Agency for Research on Cancer predicts a 22 per cent increase in the number of people developing the disease by 2020, amounting to about 412,929 cases (an increase of 75,069) [2].

Statistics also show that incidence rates of the disease are twice as high among men than women and that 59 per cent of kidney cancer cases occur in more developed countries, with the highest rates seen in North America and Europe and the lowest in Africa and Asia [2].

Although kidney cancer is the 16th most common cause of death from cancer, survival rates are relatively high in developed countries. In the USA, overall survival rates are 72 per cent after five years; the survival rate beyond five years is even higher at 92 per cent for the two thirds (64%) of cases that are diagnosed in the early stages. However, these high survival rates are not seen in lower income countries where cancers are often detected at later, more advanced stages.

In this latest report from our Continuous Update Project (CUP) – the world's largest source of scientific research on cancer prevention and survivorship through diet, weight and physical activity – we analyse worldwide research on how certain lifestyle factors affect the risk of developing kidney cancer. This includes new studies as well as those included in our 2007 Second Expert Report, *Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective* [1].

In addition to the findings in this report, other established causes of kidney cancer include:

1. Smoking:

- Smoking is a cause of kidney cancer. Current smokers have a 52 per cent increased risk of kidney cancer, and ex-smokers a 25 per cent increased risk, compared with those who have never smoked.

2. Medication:

- Painkillers containing phenacetin are known to cause cancer of the renal pelvis. Phenacetin is no longer used as an ingredient in painkillers.

3. Kidney disease:

- Polycystic kidney disease predisposes people to developing kidney cancer.

4. Hypertension:

- High blood pressure is associated with a higher risk of kidney cancer.

How the research was conducted

The global scientific research on diet, weight, physical activity and the risk of kidney cancer was systematically gathered and analysed, and then independently assessed by a panel of leading international scientists in order to draw conclusions about which of these factors increase or decrease the risk of developing the disease.

More research has been conducted in this area since our 2007 Second Expert Report [1]. In total, this new report analyses 29 studies from around the world, comprising nearly 9.7 million adults and 15,039 cases of kidney cancer.

To ensure consistency, the methodology for the Continuous Update Project remains largely unchanged from that used for our 2007 Second Expert Report [1].

A summary of the mechanisms underpinning the following findings can be found under the relevant sections of this report.

Findings

Strong evidence

There is strong evidence that being overweight or obese increases the risk of kidney cancer.

Being overweight or obese was assessed by body mass index (BMI), waist circumference and waist-to-hip ratio. The analysis of the worldwide research found a 30 per cent increased risk of kidney cancer for every 5 kg/m^2 increase; an 11 per cent increased risk for every 10 cm increase in waist circumference; and a 26 per cent increase in risk for every 0.1 unit increase in waist-to-hip ratio.

The findings on being overweight or obese remain unchanged from our 2007 Second Expert Report [1].

There is strong evidence that being tall increases the risk of kidney cancer (the taller a person is, the greater his or her risk of kidney cancer).

The analysis of research showed a 10 per cent increase in risk for every 5 cm of increased height, and the findings were the same for men and women.

It is unlikely that it is height itself that is the issue but rather, the developmental factors in the womb, and during childhood and adolescence, that influence growth that are linked to an increased risk of kidney cancer.

There is strong evidence that consuming alcoholic drinks *decreases* the risk of kidney cancer, when consuming up to 30 grams (about 2 drinks) a day. There is insufficient, specific evidence for higher levels of drinking – for example, 50 grams (about 3 drinks) or 70 grams (about 5 drinks) a day. It is also important to remember that there is strong evidence that alcohol is linked to an increased risk of five other cancers.

Limited evidence

There is some – but only limited – evidence suggesting that consuming drinking water that contains arsenic increases the risk of kidney cancer.

Water can become contaminated by arsenic as a result of natural deposits present in the earth or from agricultural and industrial practices.

The findings on consuming drinking water containing arsenic remain unchanged from our 2007 Second Expert Report [1].

Recommendations

To reduce the risk of developing kidney cancer:

1. Maintain a healthy weight.

This advice forms part of our existing Cancer Prevention Recommendations (listed on the inside back cover of this report, with full details available at wcrf.org). Our ten Cancer Prevention Recommendations are for preventing cancer in general and include maintaining a healthy weight, taking regular physical activity, eating a healthy diet and limiting alcohol consumption (if consumed at all, alcoholic drinks should be limited to a maximum of 2 drinks a day for men and 1 drink a day for women, as there is strong evidence that drinking alcohol increases the risk of breast, bowel, liver, oesophageal and mouth cancers).

References

[1] World Cancer Research Fund/American Institute for Cancer Research, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. wcrf.org/int/research-we-fund/continuous-update-project-cup/second-expert-report. 2007.

[2] Ferlay J, Soerjomataram I, Ervik M, *et al*. GLOBOCAN 2012 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2015; Available from http://globocan.iarc.fr

DIET, NUTRITION, PHYSICAL ACTIVITY AND KIDNEY CANCER

		DECREASES RISK	INCREASES RISK
STRONG EVIDENCE	Convincing		**Body fatness**[1]
	Probable	**Alcoholic drinks**[2]	**Adult attained height**[3]
LIMITED EVIDENCE	**Limited - suggestive**		Arsenic in drinking water[4]
	Limited - no conclusion	Cereals (grains) and their products, dietary fibre, vegetables, fruits, meat, poultry, fish, eggs, milk and dairy products, total fat, soft drinks, tea, coffee, carbohydrate, protein, calcium, vitamin A, retinol, vitamin C, vitamin E, beta-carotene, alpha-carotene, lycopene, beta-cryptoxanthin, lutein and zeaxanthin, flavonol, folate, vitamin B6, Seventh-day Adventist diets, physical activity, birth weight, age at menarche and energy intake	
STRONG EVIDENCE	Substantial effect on risk unlikely		

1. Body fatness marked by body mass index (BMI), waist circumference and waist-hip ratio.
2. Based on evidence for alcohol intake up to 30 grams per day (about 2 drinks a day). There is insufficient evidence for intake greater than 30 grams per day.
3. Adult attained height is unlikely to directly influence the risk of cancer. It is a marker for genetic, environmental, hormonal and nutritional factors affecting growth during the period from preconception to completion of linear growth.
4. The International Agency for Research on Cancer (IARC) has graded arsenic and arsenic compounds as Class 1 carcinogens. The grading for this entry applies specifically to inorganic arsenic in drinking water [3].

CUP Continuous Update Project

1. Summary of Panel judgements

Overall the Panel notes the strength of the evidence that body fatness and adult attained height are causes of kidney cancer and that alcoholic drinks protect against kidney cancer.

The Continuous Update Project (CUP) Panel judges as follows:

- **Body fatness: Greater body fatness (marked by BMI, waist circumference and waist-hip ratio) is a convincing cause of kidney cancer.**
- **Adult attained height: Developmental factors leading to greater linear growth (marked by adult attained height) are probably a cause of kidney cancer.**
- **Alcoholic drinks: Consumption of alcoholic drinks probably protects against kidney cancer. This is based on evidence for alcohol intakes up to 30 grams per day (about two drinks a day).**
- **Arsenic in drinking water: The evidence suggesting that consumption of arsenic in drinking water increases the risk of kidney cancer is limited.**

For a full description of the definitions of, and criteria for, the terminology of 'convincing', 'probable', 'limited – suggestive', 'limited – no conclusion' and 'substantial effect on risk unlikely', see **Appendix**.

The Panel judgements for kidney cancer are shown in the matrix on page 6.

2. Trends, incidence and survival

The kidneys are a pair of organs located at the back of the abdomen outside the peritoneal cavity. They filter waste products and water from the blood, producing urine, which empties into the bladder through the ureters. They are also important endocrine organs concerned with salt and water metabolism and maintaining blood pH, and they play a key role in vitamin D metabolism.

Renal parenchymal cancer is the most common kidney cancer, accounting for approximately 80–90 per cent of all primary kidney cancer; renal pelvis cancer accounts for most of the remainder [4]. About three-quarters of kidney cancers show clear cell histology [5]. Adults may also show papillary or sarcomatoid histology, and Wilms tumour (nephroblastoma) is a childhood cancer [4]. Renal pelvis cancer is typically transitional cell carcinoma and behaves similarly to ureteral and bladder cancer. Epidemiologic studies of kidney cancer do not always differentiate between renal parenchymal cancers and those of the renal pelvis, which likely have different risk factors.

Signs and symptoms of kidney cancer may include blood in the urine, a pain or lump in the lower back or abdomen, fatigue, weight loss, fever or swelling in the legs and ankles.

Cancers of the kidney are the 12th most common type worldwide with 338,000 cases recorded in 2012, accounting for about 2.4 per cent of all cancers. It is the 16th most common cause of death from cancer [2]. About 59 per cent of kidney cancer cases occur in more developed countries, with the highest incidence of kidney cancer in North America and Europe and the lowest in Africa and Asia [2]. The age-standardised rate of this cancer is almost ten times higher in North America than in Africa, and globally rates are twice as high in men than women [2].

Increasingly, kidney cancers are diagnosed in developed nations by radiographic imaging, such as CT scans, often performed for unrelated reasons. Kidney cancers diagnosed in this way tend to be detected at earlier stages, when they are small and asymptomatic. Survival rates depend on stage at diagnosis. In the United States of America almost two-thirds of cases (64 per cent) are diagnosed at a local stage, when the five-year survival is 92 per cent; overall survival at five years is about 70–80 per cent [6]. These high survival rates are not seen in lower-income countries, where opportunistic diagnosis following imaging for unrelated conditions is rare and cancers are detected at later, more advanced stages. For further information, see **box** on page 9.

Cancer incidence and survival

The cancer incidence rates and figures given here are those reported by cancer registries, now established in many countries. These registries record cases of cancer that have been diagnosed. However, many cases of cancer are not identified or recorded: some countries do not have cancer registries, regions of some countries have few or no records, records in countries suffering war or other disruption are bound to be incomplete, and some people with cancer do not consult a physician. Altogether, this means that the actual incidence of cancer is most probably higher than the figures given here.

The information on cancer survival shown here is for the United States of America. Survival rates are generally higher in high-income countries and other parts of the world where there are established services for screening and early detection of cancer as well as well-established treatment facilities. Survival is often a function of the stage at which a cancer is detected and diagnosed.

3. Pathogenesis

The kidneys filter blood and excrete metabolic waste products. These waste products include potential carcinogens, consumed as or derived from pharmaceuticals or foods and drinks, or through exposure from other environmental sources such as cigarette smoke. Some of these may play a role in kidney carcinogenesis.

Inherited genetic predisposition accounts for only a minority of kidney cancers [7]. Von Hippel-Lindau (VHL) syndrome is the most common, with up to 40 per cent of those inheriting the mutated VHL tumour suppressor gene developing kidney cancer [8]. Tuberous sclerosis is less common and predisposes to multiple cancer types, kidney cysts and kidney cancer [9]. About three-quarters of kidney cancers without a familial component are a clear cell type, of which about 60 per cent have a mutation in the VHL gene [10]. A further 12 per cent of non-familial kidney cancers are papillary, which are less likely to metastasise [11].

4. Other established causes

Tobacco use

Smoking is a cause of kidney cancer [12]. Both current and former smokers have an increased risk of renal cell cancer compared to people who have never smoked (52 per cent and 25 per cent respectively) [13]. Male smokers have a 54 per cent increased risk and female smokers have a 22 per cent increased risk compared with those who have never smoked, and there is a strong dose-dependent increase in risk for both men and women [14].

Medications

Analgesics containing phenacetin are a cause of cancer of the renal pelvis [15].

Kidney disease

Polycystic kidney disease predisposes people to kidney cancer [16].

Hypertension

Hypertension is associated with higher risk of kidney cancer [4].

5. Interpretation of the evidence

5.1 General

For general considerations that may affect interpretation of the evidence, see sections 3.3 and 3.5, and boxes 3.1, 3.2, 3.6 and 3.7 in the Second Expert Report [1].

'Relative risk' (RR) is used in this report to denote ratio measures of effect, including 'risk ratios', 'rate ratios', 'hazard ratios' and 'odds ratios'.

5.2 Specific

Considerations specific to cancer of the kidney include:

Classification

Different subtypes of kidney cancer likely have different aetiologies, yet some epidemiologic studies do not distinguish clear cell, the predominant parenchymal renal cancer, from papillary or other subtypes. Cancers of the renal pelvis are typically transitional cell carcinoma, which probably shares aetiologic risk factors with other transitional cell carcinomas of the ureter and bladder, in particular smoking.

Confounding

Smoking is a possible confounder or effect modifier. Most studies in the analyses adjusted for smoking, although only two of the four studies on arsenic and kidney cancer controlled for smoking.

6. Methodology

To ensure consistency, the methodology for reviewing the epidemiological evidence in the CUP remains largely unchanged from that used previously for the Second Expert Report [1]. However, based upon the experience of conducting the systematic literature reviews (SLRs) for the Second Expert Report, some modifications to the methodology were made. The literature search was restricted to Medline and included only randomised controlled trials, cohort and nested case-control studies. Due to their methodological limitations, case-control studies, although identified, were not included in the CUP Kidney SLR 2015, unlike in the 2005 SLR for the Second Expert Report.

Where possible for this update, meta-analyses for incidence and mortality were conducted separately. However, analyses combining studies on kidney cancer incidence and mortality were also conducted to explore whether the outcome can explain any heterogeneity. Separate meta-analyses were also conducted for men and women, and by geographical location, where possible.

Studies reporting mean difference as a measure of association were not included in the CUP Kidney SLR 2015, as relative risks estimated from the mean differences are not adjusted for possible confounders and thus not comparable with adjusted relative risks from other studies.

Non-linear meta-analysis was applied when the data suggested that the dose-response curve is non-linear, and when analysis detected that a threshold of exposure might be of interest. Details about the non-linear meta-analyses can be found in the CUP Kidney SLR 2015.

The CUP Kidney SLR 2015 included studies published up to 31 March 2014. For more information on methodology, see the full CUP Kidney SLR 2015 at **wcrf.org/kidney-cancer-slr-2015**

6.1 Mechanistic evidence

Where relevant, mechanistic reviews conducted for the Second Expert Report are included in this report (more details can be found in chapters 2, 4 and 6 of the Second Expert Report) [1]. These reviews have not been updated but in future will be updated as part of a systematic literature review for the CUP of the mechanistic evidence (see below). A brief summary is given of possible mechanisms for arsenic in drinking water, alcoholic drinks, body fatness and adult-attained height. Where an exposure presented in this report was previously judged as 'limited – no conclusion' or was not discussed for the Second Expert Report, there was no formal review of the mechanisms. Plausible mechanisms identified by CUP Panel members and published reviews are included in this report.

Work is under way to develop a method for systematically reviewing human, animal and other experimental studies, and in future this method will be used to conduct reviews of mechanisms for all cancer sites (for further information, see **www.wcrf.org**). A full review of the mechanistic evidence for kidney cancer will form part of this larger review.

7. Evidence and judgements

The following sections summarise the evidence identified in the CUP Kidney SLR 2015, provide a comparison with the findings from the Second Expert Report [1] and the Panel's conclusions. They also include a brief description of potential mechanisms for each exposure.

For information on the criteria for grading the epidemiological evidence, see the **Appendix** in this report. References to studies added as part of the CUP have been included; for details of references to other studies from the Second Expert Report, see the CUP Kidney SLR 2015.

7.1 Arsenic in drinking water

(Also see CUP Kidney SLR 2015: Section 4.1.2.7.2)

The CUP identified one new cohort study [17], giving a total of four studies (four publications). This study showed no significant association for either a 1 microgram per litre increase in time-weighted average exposure (drinking water) or for a 5 microgram increase in cumulative exposure (drinking water) over the 33-year period of observation (see **table 1**, CUP Kidney SLR 2015, table 51).

Three other cohort studies [18-20] were identified in the 2005 SLR. The studies were relatively small. Exposure to arsenic was measured in drinking water or well water in the areas where the study participants lived, and exposure values were individually estimated according to the time they lived in the area. A small study from Taiwan [18] showed a significant positive association (standard incidence ratio compared with general population). Neither of the two other studies reported significant associations of kidney cancer incidence with arsenic in well water [19] or with kidney cancer mortality [20] (see **table 1** (CUP Kidney SLR 2015, table 51)). A variety of measures were used to collect the data, so meta-analyses were not possible.

Table 1: Summary of cohort studies – arsenic

STUDY DESCRIPTION	NO.CASES/ YEARS OF FOLLOW-UP	SEX	RR (95% CI)	EXPOSURE/ CONTRAST
Diet, Cancer and Health, 2008 [17]	53 incident cases ~10 years follow-up	Men and women	0.88 (0.58–1.35)	For 1 µg/L increase in time-weighted average exposure (drinking water)
			0.94 (0.81–1.09)	For 5 mg increase in cumulative exposure (drinking water)
Residents in arseniasis-endemic area in Taiwan, 2001 [18]	9 incident cases ~5 years follow-up	Men and women	2.82 (1.29–5.36)	Standardised incidence ratio compared with general population in Taiwan
Finns living outside municipal drinking-water system area during 1967–1980, 1999 [19]	49 incident cases ~14 years follow-up	Men and women	Daily dose of arsenic in well water 10 years before cancer diagnosis	
			0.94 (0.39–2.27)	≥1 vs. <0.2 µg/d
			Cumulative dose of arsenic in well water 10 years before cancer diagnosis	
			0.47 (0.21–1.04)	≥2 vs. <0.5 g/d
Historical records of Mormons in Utah, 1999 [20]	~9 years follow-up	Men	1.75 (0.80–3.32)	Standardised mortality ratio compared with white male population in Utah
	~4 years follow-up	Women	1.60 (0.44–4.11)	Standardised mortality ratio compared with white female population in Utah

Ecological studies were not reviewed for the CUP Kidney SLR 2015, although nine were reviewed in the 2005 SLR. All studies showed an increased risk for the highest exposure levels compared with the lowest. Effect sizes, particularly from ecological studies in areas of high exposure levels, tend to be relatively large.

The new study identified in the CUP Kidney SLR 2015 [17] was inconsistent with the overall finding from the 2005 SLR as it showed a non-significant inverse association. The CUP Panel also considered the ecological data and the International Agency for Research on Cancer (IARC) grading of arsenic and arsenic compounds as Class 1 carcinogens.

Mechanisms

Note: This section is adapted from sections 2.4.2.4, 4.7.2.1 and 7.15.5.1 and box 4.7.2 of the Second Expert Report [1]. In the future, an updated review of mechanisms for this exposure will form part of a larger review of mechanisms (see ***section 6.1*** *in this report).*

IARC has judged arsenic and arsenic compounds to be carcinogenic to humans [3]. They may cause chromosomal abnormalities, inhibition of DNA repair and an increase in cell proliferation [21]. In addition, arsenic in drinking water is well absorbed in the gastrointestinal tract, and both inorganic arsenic and its methylated metabolites are excreted in urine. Arsenic can modify the urinary excretion of porphyrins in animals and humans. Inorganic arsenic has several genotoxic effects, including the induction of changes in chromosome structure and number, increases in sister chromatid exchanges and micronuclei, gene amplification, cell transformation and aneuploidy [22-24]. A role for inorganic arsenic as a carcinogen, such as a tumour promoter rather than a tumour initiator, has also been hypothesised [25].

CUP Panel's conclusion:

The overall evidence for a relationship between arsenic and kidney cancer was inconsistent. One study reported a significant positive association and there was strong ecological evidence, but no meta-analysis was conducted. Although arsenic is a known carcinogen and is convincingly linked to cancer risk at some sites, evidence linking it specifically to kidney cancer remains inconclusive. The CUP Panel concluded:

The evidence suggesting that consumption of arsenic in drinking water increases the risk of kidney cancer is limited.

7.2 Alcoholic drinks

(Also see CUP Kidney SLR 2015: Sections 5.4.1, 5.4.1.1, 5.4.1.2 and 5.4.1.3)

Alcohol as ethanol

The CUP identified five new or updated studies [26-30], giving a total of eight studies (12 publications) (see CUP Kidney SLR 2015, table 63, for a full list of references). All seven studies (seven estimates) reporting on kidney cancer incidence reported an inverse association when comparing the highest and the lowest categories, of which six were statistically significant (see CUP Kidney SLR 2015, figure 53).

Seven of the eight studies were included in the dose-response meta-analysis (*n* = 3,525), which showed a statistically significant 8 per cent decreased risk per 10 grams of alcohol per day (RR 0.92 (95% CI 0.86–0.97)) (see **figure 1** (CUP Kidney SLR 2015, figure 54)). High heterogeneity was observed (I^2 = 55%). The overall heterogeneity appeared to be explained by the weaker inverse association (compared with other studies) reported by one study, mainly for men [26]. The heterogeneity decreased after exclusion of this study (I^2 = 25%). There was evidence of small study bias with Egger's test (p = 0.001). Two smaller studies found stronger inverse associations than the other studies (see CUP Kidney SLR 2015, figure 55). The highest category reported in studies is 30 grams or more per day (see Kidney CUP SLR 2015, figure 53). There is insufficient specific evidence on higher levels of drinking – for example, 50 grams or 70 grams per day – to assess the effect of drinking alcohol at these levels on kidney cancer (see CUP Kidney SLR 2015, figure 56).

Figure 1: Dose-response meta-analysis of alcohol (as ethanol) intake and kidney cancer, per 10 g per day



When stratified by sex, the dose-response meta-analysis showed a decreased risk per 10 grams per day, which was statistically significant in women but not men (see **table 2** and CUP Kidney SLR 2015, figure 57).

Table 2: Summary of CUP 2015 stratified dose-response meta-analysis – alcohol

ANALYSIS	INCREMENT	RR (95% CI)	I^2	NO. STUDIES	NO. CASES
MEN	Per 10 g/day	0.92 (0.84-1.00)	71%	3	1,796
WOMEN	Per 10 g/day	0.81 (0.68-0.96)	44%	5	1,318

The results were consistent in analyses conducted by type of alcoholic drink consumed (as ethanol) for beer, wine and spirits but reached statistical significance only for beer (RR = 0.77 (95% CI 0.65–0.92) per 10 grams of alcohol per day).

One study [31] was not included in any of the CUP analyses because it did not report sufficient data.

The CUP 2015 findings were consistent with the dose-response meta-analysis from the 2005 SLR, which included three studies (one did not adjust for smoking) and showed a significant inverse association per serving per day (RR = 0.48 (95% CI 0.25–0.90)). The effect observed in the CUP Kidney SLR 2015 was smaller but included more than double the number of studies and many more cases of kidney cancer. The results strengthen the evidence showing a decreased risk, and both the 2005 SLR and the CUP Kidney SLR 2015 consistently show no adverse effect of consuming alcohol.

Published pooled analyses and meta-analyses

One published pooled analysis of cohort studies [32] and two meta-analyses [33, 34] on alcohol and kidney cancer were identified in the CUP Kidney SLR 2015. The pooled analysis reported a significant decreased risk when comparing the highest and lowest drinkers and the dose-response meta-analysis showed a statistically significant 19 per cent decreased risk per 10 grams per day. When the studies identified by the CUP 2015 (but not in the pooled analysis) were combined with the results of the pooled analysis, a significant 12 per cent decreased risk was observed per 10 grams per day. Both meta-analyses reported significant decreased risks when comparing the highest and the lowest drinkers (26 per cent decreased risk (12.5–49.9 grams per day compared with non-drinking) [33] and 29 per cent decreased risk (for the highest compared to the lowest alcohol intake) [34]). Results from the CUP and the pooled analyses are presented in **table 3**.

Table 3: Summary of CUP 2015 meta-analysis and published pooled analyses – alcohol

ANALYSIS	INCREMENT	RR (95% CI)	I^2	NO. STUDIES	NO. CASES	FACTORS ADJUSTED FOR
CUP Kidney Cancer SLR 2015	Per 10 g/day	0.92 (0.86-0.97)	55%	7	3,525	
Pooling Project of Cohort Studies [32]	≥ 15 g/day vs. non-drinker	0.72 (0.60-0.86)	-	12	1,430	Adjusted for age, history of hypertension (Y/N), BMI, pack years of smoking (continuous), combination of parity and age at first birth (age at first birth < 25 years and parity of 1 or 2, age at first birth ≥ 25 years and parity of 1 or 2 or nulliparous, age at first birth < 25 years and parity of ≥ 3, and age at first birth ≥ 25 years and parity of ≥ 3), and total energy intake (kcal/day, continuous).
	Per 10 g/day ethanol intake*	0.81 (0.74-0.90)				
CUP Kidney Cancer SLR 2015 additional analysis: Pooling Project of Cohort Studies [32] combined with studies from the CUP**	Per 10 g/day	0.88 (0.79-0.97)	80%	15	≈4,179***	

** Participants in the Pooling Project with intake >30 g/day were excluded*

*** Pooling Project meta-analysed with three studies from the CUP [26, 27, 29]*

**** For the category ≥ 15 g/day*

Mechanisms

*Note: In the future, an updated review of mechanisms for this exposure will form part of a larger review of mechanisms (see **section 6.1** in this report).*

The mechanisms whereby alcohol might reduce kidney cancer risk are unclear, although there are several hypotheses. Moderate alcohol intake is related to reduced risks of hyperinsulinemia and type 2 diabetes, which may be determinants of kidney cancer [32, 35].

In addition, alcoholic beverages may contain antioxidant phenolic compounds, which might lower kidney cancer risk through various mechanisms [36].

A further potential mechanism may be related to the diuretic effect of alcohol, which may reduce exposure of kidney epithelial cells to carcinogenic solutes because of dilution and shorter duration of exposure [32, 37].

CUP Panel's conclusion:

The evidence was consistent with a clear inverse dose-response relationship for alcohol and kidney cancer. There was evidence of heterogeneity, which appeared to be due to differences in the size of the effect. When stratified by sex, the association was significant for women but not for men. The results were consistent with the findings from the 2005 SLR, but with more studies and cases. The results were also consistent with findings from a published pooled analysis. The protective effect is apparent up to 30 grams per day (about 2 drinks a day). There is insufficient evidence beyond 30 grams per day. There is evidence of plausible mechanisms in humans. The CUP Panel concluded:

Consumption of alcoholic drinks probably protects against kidney cancer. This is based on evidence for alcohol intakes up to 30 grams per day (about two drinks a day).

7.3 Body fatness

(Also see CUP Kidney SLR 2015: Sections 8.1, 8.2.1 and 8.2.3)

The Panel interpreted body mass index (BMI), waist circumference and waist-hip ratio as measures of body fatness. These anthropometrical measures are imperfect and cannot distinguish between lean mass and body fat.

The CUP identified 28 studies (36 publications) on body fatness, all of which reported on BMI, three of which also reported on waist circumference and four of which also reported on waist-hip ratio.

Body mass index

The CUP identified 14 new or updated studies (17 publications) [29, 38-53], giving a total of 28 studies (37 articles) (see CUP Kidney SLR 2015, table 140, for a full list of references). Of 30 estimates (21 studies) reporting on kidney cancer incidence, 28 showed a positive association when comparing the highest and the lowest categories, 14 of which were significant. One other study reported a positive association for women and an inverse association for men, both of which were not significant. Both studies reporting on kidney cancer mortality reported positive associations for both men and women, one of which was significant in women (see CUP Kidney Cancer SLR 2015, figure 115).

Twenty-three of the 28 studies were included in the dose-response meta-analysis (n = 15,575), which showed a statistically significant 30 per cent increased risk per 5 kg/m^2 (RR 1.30 (95% CI 1.25–1.35)) (see **figure 2** (CUP Kidney SLR 2015, figure 116)). Moderate heterogeneity was observed (I^2 = 39%).

Figure 2: Dose-response meta-analysis of BMI and kidney cancer, per 5 kg/m²



When stratified by outcome, a dose-response meta-analysis showed a significant increase risk per 5 kg/m^2 for kidney cancer incidence and for mortality. When stratified by sex, there was significant increased risk per 5 kg/m^2 for both men and women. Finally, when stratified by geographical location, there was a significant increased risk per 5 kg/m^2 in North American, European and Asian studies (see **table 4** and CUP Kidney SLR 2015, figures 119 and 120).

Table 4: Summary of CUP 2015 stratified dose-response meta-analyses – BMI

ANALYSIS	INCREMENT	RR (95% CI)	I^2	NO. STUDIES	NO. CASES
Incidence	Per 5 kg/m^2	1.30 (1.25-1.36)	39%	21	14,148
Mortality	Per 5 kg/m^2	1.32 (1.01-1.71)	37%	2	1,427
Men	Per 5 kg/m^2	1.29 (1.23-1.36)	30%	17	8,741
Women	Per 5 kg/m^2	1.28 (1.24-1.32)	0%	17	5,708
North America	Per 5 kg/m^2	1.29 (1.20-1.39)	56%	10	4,117
Europe	Per 5 kg/m^2	1.27 (1.24-1.31)	0%	9	8,739
Asia	Per 5 kg/m^2	1.47 (1.26-1.72)	16%	4	2,719

Four studies [54-57] were not included in any of the CUP analyses because they did not report sufficient data.

The CUP 2015 findings were similar to the dose-response meta-analysis from the 2005 SLR, which included seven studies and showed a significant positive association per 5 kg/m^2 (RR 1.31 (95% CI 1.24–1.39), *n* = 8,602) for incidence and mortality combined, the CUP 2015 included more than three times as many studies and many more cases of kidney cancer.

Published pooled analyses and meta-analyses

Results from three pooled analyses [58-60] and three meta-analyses [61-63] on BMI and kidney cancer were identified by the CUP Kidney SLR 2015. All published pooled and meta-analyses reported positive associations for continuous and highest estimates compared with lowest estimates, consistent with the CUP Kidney SLR 2015, but not all were statistically significant. The CUP included more kidney cancer cases than any of the published pooled analyses. All three meta-analyses reported significant positive associations for continuous estimates. Results from the published pooled analyses are presented in **table 5**.

Table 5: Summary of CUP 2015 meta-analyses and published pooled analysis – BMI

ANALYSIS	INCREMENT/ CONTRAST	RR (95% CI)	I^2	NO. STUDIES	NO. CASES	FACTORS ADJUSTED FOR
CUP Kidney SLR 2015	Per 5 kg/m^2	1.30 (1.25-1.35)	39%	23	15,575	
Asia-Pacific Cohort Studies Collaboration [60]	BMI ≥30 vs. 18.5–24.9 kg/m^2	1.59 (0.78-3.24)	-	39	93	Adjusted for age and smoking
	Per 5 kg/m^2	1.20 (0.86-1.66)				
Metabolic Syndrome and Cancer Project – Me-Can project [58]	BMI 31.7 vs. 21.5 kg/m^2 (men)	1.51 (1.13-2.03)	-	7	592	Adjusted for categories of birth year and age at measure-ment, and stratified at cohort
	BMI 31.7 vs. 20.0 kg/m^2 (women)	2.21 (1.32-3.70)		7	263	
Prospective Studies Collaboration [59]	Per 5 kg/m^2	1.23 (1.06-1.43)	-	57	422	Adjusted for study, sex, age at risk (in 5-year groups) and baseline smoking status

Waist circumference

The CUP identified three studies (three publications) [48, 51, 64]. No studies were identified in the 2005 SLR (see CUP Kidney SLR 2015, table 150, for a full list of references). All three studies reporting on waist circumference and the incidence of kidney cancer showed a non-significant positive association when comparing the highest and the lowest categories (see CUP Kidney SLR 2015, figure 128).

All three studies were included in the dose-response meta-analysis (*n* = 751), which showed a statistically significant 11 per cent increased risk per 10 centimetres (RR 1.11 (95% CI 1.05–1.19)) (**see figure 3** (CUP Kidney SLR 2015, figure 129)). No heterogeneity was observed (I^2 = 0%).

No cohort studies were identified in the 2005 SLR.

Figure 3: Dose-response meta-analysis of waist circumference and kidney cancer, per 10 cm



Waist-hip ratio

The CUP identified three new studies (three publications) [46, 48, 51], giving a total of four studies (five publications) in the CUP (see CUP Kidney SLR 2015, table 154, for a full list of references). All four studies reporting on waist-hip ratio and the incidence of kidney cancer showed a positive association when comparing the highest and the lowest categories, of which two were statistically significant (see Kidney Cancer SLR 2015, figure 128).

Three studies were included in the dose-response meta-analysis (*n* = 751), which showed a statistically significant 26 per cent increased risk per 0.1 unit (RR 1.26 (95% CI 1.18–1.36)) (see **figure 4** (CUP Kidney SLR 2015, figure 132). No heterogeneity was observed (I^2 = 0%).

Only one cohort study was identified in the 2005 SLR, and no meta-analysis could be conducted.

Figure 4: Dose-response meta-analysis of waist-hip ratio and kidney cancer, per 0.1 unit



Mechanisms

*Note: This is adapted from sections 6.1.3.1 and 7.15.5.4 of the Second Expert Report [1]. An updated review of mechanisms for this exposure will form part of a larger review of mechanisms (see **section 6.1** in this report).*

The specific mechanisms whereby obesity increases risk of kidney cancer are speculative, but excess body fat directly affects circulating insulin levels [65] and it increases the risk of high blood pressure [66] – factors positively related to the development of kidney cancer [67]. In addition, obesity is associated with a low-grade chronic inflammatory state. Such chronic inflammation is accompanied by metabolic and physiological alterations that could increase cancer risk. In obesity, adipose tissue is characterised by macrophage infiltration, and these macrophages are an important source of inflammatory signals. The adipocyte (fat cell) produces pro-inflammatory factors, and obese individuals have elevated concentrations of circulating tumour necrosis factor-alpha, interleukin-6 and C-reactive protein compared with lean people, as well as of leptin, which also functions as an inflammatory cytokine [68].

CUP Panel's conclusion:

Body fatness is reflected by BMI and measures of abdominal girth. There was consistent epidemiological evidence for an association between various measures of body fatness and kidney cancer, with a clear dose-response relationship. The association was still apparent when stratified by outcome, sex and geographical location. Results from several published pooled analyses and meta-analyses were also consistent with the CUP results in the direction of the effect, although not all showed findings that were statistically significant. Multiple mechanisms have been demonstrated in humans through which obesity and energy balance might increase kidney cancer risk. The CUP Panel concluded:

Greater body fatness (marked by BMI, waist circumference and waist-hip ratio) is a convincing cause of kidney cancer.

7.4 Adult attained height

(Also see CUP Kidney SLR 2015: Section 8.3.1)

The CUP Kidney SLR 2015 identified six new studies (six publications) [29, 47, 51, 69-71], giving a total of 11 studies (11 publications) (see CUP Kidney SLR 2015, table 158, for a full list of references).

Of the four studies (eight estimates) reporting on kidney cancer incidence, three showed a positive association when comparing the highest and the lowest categories, which was statistically significant in one study, and the fourth study showed an inverse association for men and a positive association for women, both of which were not significant. Of the two studies reporting on kidney cancer mortality, one showed a non-significant inverse association and one showed a non-significant positive association (see Kidney Cancer SLR 2015, figure 134).

Ten studies were included in the dose-response meta-analysis (n = 9,874), which showed a statistically significant 10 per cent increased risk per 5 centimetres (RR 1.10 (95% CI 1.08–1.12)) (see **figure 5** (CUP Kidney SLR 2015, figure 135)). No heterogeneity was observed (I^2 = 0%).

Figure 5: Dose-response meta-analysis of height and kidney cancer, per 5 cm

When stratified by sex, the dose-response meta-analysis showed a significant increased risk per 5 centimetres in men and women (see **table 6** and CUP Kidney SLR 2015, figure 139).

Table 6: Summary of CUP 2015 stratified dose-response meta-analysis – height

ANALYSIS	INCREMENT	RR (95% CI)	I^2	NO. STUDIES	NO. CASES
MEN	Per 5 cm	1.10 (1.06-1.13)	5%	9	1,272
WOMEN	Per 5 cm	1.10 (1.07-1.14)	11%	6	409

One study [72] was not included in any of the CUP analyses because it did not report sufficient data.

The CUP Kidney SLR 2015 findings showed a significant positive dose-response relationship between adult attained height and kidney cancer, which strengthened the findings from the 2005 SLR, in which the meta-analysis showed no significant association (RR = 1.13 (0.96–1.33)). The CUP Kidney SLR 2015 included five times as many studies and many more cases of kidney cancer and reported results per 10 centimetres compared with 5 centimetres in the 2005 SLR.

Published pooled analyses and meta-analysis

Results from one published pooled analysis of cohort studies on height and kidney cancer were identified in the CUP Kidney SLR 2015 [73]. The study, which contained very few cases of kidney cancer, reported no significant associations between height and kidney cancer risk in men or women. Results from the CUP Kidney SLR 2015 and the pooled analysis are presented in **table 7**.

Table 7: Summary of CUP 2015 meta-analysis and pooled analyses – height

ANALYSIS	INCREMENT	RR (95% CI)	I^2	NO. STUDIES	NO. CASES	FACTORS ADJUSTED FOR
CUP Kidney SLR 2015	Per 5 cm	1.10 (1.08-1.12)	0	10	9,874	
Asia-Pacific Cohort Studies Collaboration [73]	Per 6 cm (men)	1.04 (0.83-1.31)		38	67	Age, study and year of birth adjusted
	Per 6 cm (women)	1.21 (0.81-1.83)			23	

Mechanisms

*Note: This is adapted from section 6.2.1.3 and box 2.4 of the Second Expert Report [1]. An updated review of mechanisms for this exposure will form part of a larger review of mechanisms (see **section 6.1** in this report).*

Adult height is related to the rate of growth during fetal life and childhood [74, 75]. The number of cell divisions in fetal life and childhood, health and nutrition status in childhood, and age of sexual maturity are all determined by the hormonal microenvironment (plasma levels of growth factors and oestrogens and their respective binding protein). Conversely, total body adiposity and visceral adiposity can alter the circulating concentration of some plasma hormones and their respective binding protein (insulin, sex steroids, insulin-like growth factors (IGFs)) [76]. Many of these mechanisms, such as early-life nutrition affecting body composition, altered circulating and free hormone profiles, can modulate the rate of tissue growth and sexual maturation. It is therefore plausible that nutritional factors that affect height could also influence cancer risk. Specific tissues in taller people are exposed to higher levels of insulin, pituitary-derived growth hormone and IGFs, and thus may have undergone more cell divisions. This increased number of cell divisions may contribute to greater potential for error during DNA replication, resulting in an increased risk of developing cancer [77, 78].

Therefore, adult attained height is a marker of an aggregated fetal and childhood experience and is clearly also a surrogate for important nutritional exposures, which affect several hormonal and metabolic axes and which may influence cancer risk.

CUP Panel's conclusion:

The overall evidence was generally consistent with a clear dose-response relationship. When stratified by sex, the association remained significant in both men and women. The results strengthened the findings from the 2005 SLR. The results of the published pooled analysis, with few cases, showed an increased risk but were not statistically significant. There is evidence of plausible mechanisms operating in humans. The CUP Panel concluded:

Developmental factors leading to greater linear growth (marked by adult attained height) are probably a cause of kidney cancer.

7.5 Other

Other exposures were evaluated. However, data were either of too low quality or too inconsistent, or the number of studies too few, to allow conclusions to be reached. The list of exposures judged as 'Limited – no conclusion' is summarised in the matrix on page 6.

Evidence for the following exposures, previously judged as 'Limited – no conclusion' in the Second Expert Report [1], remains unchanged after updating the analyses with new data identified in the CUP Kidney SLR 2015: Cereals (grains) and their products, vegetables, fruits, meat, poultry, fish, eggs, milk and dairy products, total fat, soft drinks, tea, carbohydrate, protein, vitamin A, retinol, vitamin C, vitamin E, beta-carotene, flavonol, Seventh-day Adventist diets, physical activity, birth weight, and energy intake.

In addition, evidence for the following new exposures, for which no judgement was made in the Second Expert Report, is too limited to draw any conclusions: dietary fibre, vitamin B6, folate, calcium, alpha-carotene, beta-cryptoxanthin, lycopene, lutein and zeaxanthin.

8. Comparison with the Second Expert Report

Overall the evidence from the additional cohort studies identified by the CUP was consistent with that reviewed as part of the Second Expert Report [1]. Much of the new evidence was related to height, which has been upgraded from 'limited – no conclusion' to 'probably a cause', and also to alcoholic drinks, for which the conclusion from the Second Expert Report was upgraded from 'Limited – no conclusion' alcoholic drinks (for a protective effect) and 'Substantial effect on risk unlikely' alcoholic drinks (for an adverse effect) to 'probably protects' against kidney cancer (up to 30 grams a day).

9. Conclusions

The CUP Panel concluded:

- **Body fatness: Greater body fatness (marked by BMI, waist circumference and waist-hip ratio) is a convincing cause of kidney cancer.**
- **Adult attained height: Developmental factors leading to greater linear growth (marked by adult attained height) are probably a cause of kidney cancer.**
- **Alcoholic drinks: Consumption of alcoholic drinks probably protects against kidney cancer. This is based on evidence for alcohol intakes up to 30 grams per day (about two drinks a day).**
- **Arsenic in drinking water: The evidence suggesting that consumption of arsenic in drinking water increases the risk of kidney cancer is limited.**

For a full description of the definitions of, and criteria for, the terminology of 'convincing', 'probable', 'limited – suggestive', 'limited – no conclusion' and 'substantial effect on risk unlikely', see **Appendix**.

The CUP database is being continually updated for all cancers. The Recommendations for Cancer Prevention will be reviewed in 2017 when the Panel has reviewed the conclusions for the other cancers.

Acknowledgements

Panel Members

CHAIR - **Alan Jackson** CBE MD FRCP FRCPath FRCPCH FAfN
University of Southampton
Southampton, UK

DEPUTY CHAIR - **Hilary Powers** PhD RNutr
University of Sheffield
Sheffield, UK

Elisa Bandera MD PhD
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ, USA

Steven Clinton MD PhD
The Ohio State University
Columbus, OH, USA

Edward Giovannucci MD ScD
Harvard School of Public Health
Boston, MA, USA

Stephen Hursting PhD MPH
University of North Carolina at Chapel Hill
Chapel Hill, NC, USA

Michael Leitzmann MD DrPH
Regensburg University
Regensburg, Germany

Anne McTiernan MD PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

Inger Thune MD PhD
Oslo University Hospital and University of Tromsø
Norway

Ricardo Uauy MD PhD
Instituto de Nutrición y Technología de los Alimentos
Santiago, Chile

Observers

Elio Riboli MD ScM MPH
Imperial College London
London, UK

Isabelle Romieu MD MPH ScD
International Agency for Research on Cancer
Lyon, France

Research Team

Teresa Norat PhD
Principal Investigator
Imperial College London
London, UK

Dagfinn Aune MSc
Research Associate
Imperial College London
London, UK

Deborah Navarro-Rosenblatt MSc
Research Associate
Imperial College London
London, UK

Leila Abar MSc
Research Associate
Imperial College London
London, UK

Darren Greenwood PhD
Statistical Advisor
Senior Lecturer in Biostatistics
University of Leeds
Leeds, UK

WCRF Executive

Kate Allen PhD
Executive Director, Science and Public Affairs
WCRF International

Deirdre McGinley-Gieser
Senior Vice President for Programs
AICR

Secretariat

HEAD - **Rachel Thompson** PhD RNutr
Head of Research Interpretation
WCRF International

Susannah Brown MSc
Science Programme Manager
(Research Evidence)
WCRF International

Susan Higginbotham PhD RD
Vice President of Research
AICR

Rachel Marklew MSc RNutr
Science Programme Manager
(Research Interpretation)
WCRF International

Giota Mitrou PhD
Head of Research Funding and
Science External Relations
WCRF International

Martin Wiseman FRCP FRCPath FAfN
Medical and Scientific Adviser
WCRF International

Abbreviations

AICR	American Institute for Cancer Research
BMI	Body mass index
CI	Confidence interval
CT	Computerised tomography
CUP	Continuous Update Project
DNA	Deoxyribonucleic acid
IARC	International Agency for Research on Cancer
IGF	Insulin-like growth factor
No.	Number
RR	Relative risk
SLR	Systematic literature review
VHL	von Hippel-Lindau
WCRF	World Cancer Research Fund
n	Number of cases

Glossary

Adjustment
A statistical tool for taking into account the effect of known confounders (see confounder).

Aneuploidy
The presence of an abnormal number of chromosomes in a cell, such as having 45 or 47 chromosomes when 46 are expected.

Bias
In epidemiology, deviation of an observed result from the true value in a particular direction (systematic error) due to factors pertaining to the observer or to study design or analysis. See also selection bias.

Body mass index (BMI)
Body weight expressed in kilograms divided by the square of height expressed in metres (BMI = kg/m^2). It provides an indirect measure of body fatness. Also called Quetelet's Index.

Carcinogen
Any substance or agent capable of causing cancer.

Carcinoma
Malignant tumour derived from epithelial cells, usually with the ability to spread into the surrounding tissue (invasion) and produce secondary tumours (metastases).

Case-control study
An epidemiological study in which the participants are chosen based on their disease or condition (cases) or lack of it (controls), to test whether distant or recent history of an exposure such as smoking, genetic profile, alcohol consumption or dietary intake is associated with the risk of disease.

Cell transformation
Transformation is the genetic alteration of a cell resulting from the direct uptake and incorporation of genetic material from outside the cell (exogenous DNA) from its surroundings, taken up through the cell membrane(s).

Cohort study
A study of a (usually large) group of people whose characteristics are recorded at recruitment (and sometimes later), followed up for a period of time during which outcomes of interest are noted. Differences in the frequency of outcomes (such as disease) within the cohort are calculated in relation to different levels of exposure to factors of interest, for example, smoking, alcohol consumption, diet and exercise. Differences in the likelihood of a particular outcome are presented as the relative risk, comparing one level of exposure to another.

Confidence interval (CI)
A measure of the uncertainty in an estimate, usually reported as 95 per cent confidence interval (CI), which is the range of values within which there is a 95 per cent chance that the true value lies. For example, the effect of smoking on the relative risk of lung cancer in one study may be expressed as 10 (95% CI 5–15). This means that in this particular analysis, the point estimate of the relative risk was calculated as 10, and that there is a 95 per cent chance that the true value lies between 5 and 15.

Confounder
A variable, within a specific epidemiological study, that is associated with both an exposure and the disease but is not in the causal pathway from the exposure to the disease. If not adjusted for, this factor may distort the true exposure–disease relationship. An example is that smoking is related both to coffee drinking and to risk of lung cancer and thus, unless adjusted for (controlled) in studies, might make coffee drinking appear falsely as a possible cause of lung cancer.

CT scans
A computerized tomography (CT) scan combines a series of X-ray images taken from different angles and uses computer processing to create cross-sectional images, or slices, of the bones, blood vessels and soft tissues inside the body.

Deoxyribonucleic acid (DNA)
The double-stranded, helical molecular chain found in the chromosomes within the nucleus of cells, which carries the genetic information.

Dose-response
A term derived from pharmacology that describes the degree to which an effect changes with the level of an exposure; for instance, the intake of a drug or food (see Second Expert Report, box 3.2 [1]).

Ecological studies
Ecological studies are observational studies of the effect of risk-modifying factors on health or other outcomes defined by the level at which data are analysed, namely at the population or group level rather than the individual level. Both risk-modifying factors and outcomes are averaged for the populations in each geographical or temporal unit, and then compared using standard statistical methods. Ecological studies are often used to measure the prevalence and incidence of disease, particularly when disease is rare.

Egger's test
A statistical test for small study effects such as publication bias.

Exposure
A factor to which an individual may be exposed to varying degrees, such as intake of a food, level or type of physical activity, or aspect of body composition.

Familial
Relating to or occurring in a family or its members.

Gene amplification
Gene amplification is an increase in the number of copies of a gene sequence. Cancer cells sometimes produce multiple copies of genes in response to signals from other cells or their environment.

Heterogeneity
A measure of difference between the results of different studies addressing a similar question in meta-analysis. The degree of heterogeneity may be calculated statistically, for example, using the I^2 test.

Hormone
A substance secreted by specialised cells that affects the structure and/or function of other cells or tissues in another part of the body.

Incidence rates
The number of new cases of a condition appearing during a specified period of time expressed relative to the size of the population, for example, 60 new cases of breast cancer per 100,000 women per year.

Inflammation
The immunologic response of tissues to injury or infection. Inflammation is characterised by accumulation of white blood cells that produce several bioactive chemicals (cytokines), causing redness, heat, pain and swelling.

Insulin
A hormone secreted by the pancreas that promotes the uptake and utilisation of glucose, particularly in the liver and muscles. Inadequate secretion of, or tissue response to, insulin leads to diabetes mellitus.

Insulin-like growth factor
The insulin-like growth factors (IGFs) are proteins with high similarity to insulin. IGFs are part of a complex system that cells use to communicate with their environment.

Malignant
The capacity of a tumour to spread to surrounding tissue (invasion) or to other sites in the body (metastasis).

Meta-analysis
The process of using statistical methods to combine the results of different studies.

Metastasis
The spread of malignant cancer cells to distant locations around the body from the original site.

Micronuclei
Small nucleus that forms whenever a chromosome or a fragment of a chromosome is not incorporated into one of the daughter nuclei during cell division.

Mutation
In biology, a mutation is a permanent change of the nucleotide sequence of the genome (an organism's complete set of DNA).

Odds ratio (OR)

A measure of the risk of an outcome such as cancer, associated with an exposure of interest, used in case-control studies, approximately equivalent to the relative risk (RR).

Pathogenesis
The origin and development of disease. The mechanisms by which causal factors increase the risk of disease.

Pharmaceuticals
More commonly known as medicines or drugs, used to diagnose, cure, treat, or prevent disease.

Physical activity
Any movement using skeletal muscles.

Pooled analysis (see pooling)

Pooling
In epidemiology, a type of study in which original individual-level data from two or more original studies are obtained, combined and analysed.

Publication bias
A bias in the overall balance of evidence in the published literature due to selective publication. Not all studies carried out are published, and those that are may differ from those that are not. The likelihood of publication bias can be tested, for example, with either Begg's or Egger's tests.

Randomised controlled trial (RCT)
A study in which a comparison is made between one intervention (often a treatment or prevention strategy) and another (control). Sometimes the control group receives an inactive agent (a placebo). Groups are randomised to one intervention or the other, so that any difference in outcome between the two groups can be ascribed with confidence to the intervention. Usually neither investigators nor subjects know to which condition they have been randomised; this is called 'double-blinding'.

Relative risk (RR)
The ratio of the rate of disease or death among people exposed to a factor compared with the rate among the unexposed, usually used in cohort studies.

Selection bias
Bias arising from the procedures used to select study participants and from factors influencing participation.

Sister chromatid exchanges
The exchange of genetic material between two identical sister chromatids.

Standardised mortality ratio
A quantity, expressed as either a ratio or percentage, quantifying the increase or decrease in death of a study cohort with respect to the general population.

Statistical significance

The probability that any observed result might not have occurred by chance. In most epidemiologic work, a study result whose probability is less than 5 per cent ($p < 0.05$) is considered sufficiently unlikely to have occurred by chance to justify the designation 'statistically significant' (see confidence interval).

Systematic literature review (SLR)
A means of compiling and assessing published evidence that addresses a scientific question with a predefined protocol and transparent methods.

Tumour initiator
An agent that damages cellular DNA, a necessary condition for the production of a new tumour.

Tumour promoter
A chemical, complex of chemicals or biological agent that promotes a later stage of carcinogenesis, called tumor promotion, by altering expression of the genetic information, rather than altering the structure of DNA.

Tumour suppressor gene
A gene that protects a cell from one step on the path to cancer. When this gene mutates to cause a loss or reduction in its function, the cell can progress to cancer, usually in combination with other genetic changes.

References

1. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. **wcrf.org/int/research-we-fund/continuous-update-project-cup/second-expert-report**. 2007.
2. Ferlay J, Soerjomataram I, Dikshit R, *et al.* Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359-86.
3. International Agency for Research on Cancer. Arsenic, metals, fibres, and dusts. *IARC Monogr Eval Carcinog Risks Hum* 2012; 100: 11-465.
4. Chow WH, Dong LM, and Devesa SS. Epidemiology and risk factors for kidney cancer. *Nat Rev Urol* 2010; 7: 245-57.
5. Larkin JM, Kipps EL, Powell CJ, *et al*. Systemic therapy for advanced renal cell carcinoma. *Ther Adv Med Oncol* 2009; 1: 15-27.
6. Siegel RL, Miller KD, and Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; 65: 5-29.
7. Rini BI, Campbell SC, and Escudier B. Renal cell carcinoma. *Lancet* 2009; 373: 1119-32.
8. Meister M, Choyke P, Anderson C, *et al.* Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease. *Clin Radiol* 2009; 64: 589-600.
9. Lopez JI. Renal tumors with clear cells. A review. *Pathol Res Pract* 2013; 209: 137-46.
10. Maher ER. Genomics and epigenomics of renal cell carcinoma. *Semin Cancer Biol* 2013; 23: 10-7.
11. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. *Genome Res* 2012; 22: 2089-100.
12. International Agency for Research on Cancer. Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 1-538.
13. Gandini S, Botteri E, Iodice S, *et al*. Tobacco smoking and cancer: a meta-analysis. *Int J Cancer* 2008; 122: 155-64.
14. Hunt JD, van der Hel OL, McMillan GP, *et al.* Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. *Int J Cancer* 2005; 114: 101-8.
15. Gago-Dominguez M, Yuan JM, Castelao JE, *et al*. Regular use of analgesics is a risk factor for renal cell carcinoma. *Br J Cancer* 1999; 81: 542-8.
16. Marple JT, MacDougall M, and Chonko AM. Renal cancer complicating acquired cystic kidney disease. *J Am Soc Nephrol* 1994; 4: 1951-6.
17. Baastrup R, Sorensen M, Balstrom T, *et al*. Arsenic in drinking-water and risk for cancer in Denmark. *Environ Health Perspect* 2008; 116: 231-7.
18. Chiou HY, Chiou ST, Hsu YH, *et al.* Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. *Am J Epidemiol* 2001; 153: 411-8.
19. Kurttio P, Pukkala E, Kahelin H, *et al*. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. *Environ Health Perspect* 1999; 107: 705-10.
20. Lewis DR, Southwick JW, Ouellet-Hellstrom R, *et al.* Drinking water arsenic in Utah: A cohort mortality study. *Environ Health Perspect* 1999; 107: 359-65.
21. Abernathy CO, Liu YP, Longfellow D, *et al*. Arsenic: health effects, mechanisms of actions, and research issues. *Environ Health Perspect* 1999; 107: 593-7.
22. Wu MM, Kuo TL, Hwang YH, *et al.* Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. *Am J Epidemiol* 1989; 130: 1123-32.
23. Warner ML, Moore LE, Smith MT, *et al.* Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. *Cancer Epidemiol Biomarkers Prev* 1994; 3: 583-90.
24. International Agency for Research on Cancer. Genetic and related effects: An updating of selected IARC monographs from Volumes 1 to 42. *IARC Monogr Eval Carcinog Risks Hum Suppl* 1987; 6: 1-729.

25. Stohrer G. Arsenic: opportunity for risk assessment. *Arch Toxicol* 1991; 65: 525-31.
26. Lew JQ, Chow WH, Hollenbeck AR, *et al*. Alcohol consumption and risk of renal cell cancer: the NIH-AARP diet and health study. *Br J Cancer* 2011; 104: 537-41.
27. Allen NE, Balkwill A, Beral V, *et al.* Fluid intake and incidence of renal cell carcinoma in UK women. *Br J Cancer* 2011; 104: 1487-92.
28. Schouten LJ, van Dijk BA, Oosterwijk E, *et al*. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 3543-50.
29. Setiawan VW, Stram DO, Nomura AM, *et al.* Risk factors for renal cell cancer: the multiethnic cohort. *Am J Epidemiol* 2007; 166: 932-40.
30. Wilson RT, Wang J, Chinchilli V, *et al*. Fish, vitamin D, and flavonoids in relation to renal cell cancer among smokers. *Am J Epidemiol* 2009; 170: 717-29.
31. Kato I, Nomura AM, Stemmermann GN, *et al*. Prospective study of the association of alcohol with cancer of the upper aerodigestive tract and other sites. *Cancer Causes Control* 1992; 3: 145-51.
32. Lee JE, Hunter DJ, Spiegelman D, *et al.* Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. *J Natl Cancer Inst* 2007; 99: 801-10.
33. Bellocco R, Pasquali E, Rota M, *et al*. Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis. *Ann Oncol* 2012.
34. Song DY, Song S, Song Y, *et al.* Alcohol intake and renal cell cancer risk: a meta-analysis. *Br J Cancer* 2012; 106: 1881-90.
35. Pelucchi C, Galeone C, Montella M, *et al.* Alcohol consumption and renal cell cancer risk in two Italian case-control studies. *Ann Oncol* 2008; 19: 1003-8.
36. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? *Lancet* 1994; 344: 721-4.
37. Nicodemus KK, Sweeney C, and Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. *Int J Cancer* 2004; 108: 115-21.
38. Southard EB, Roff A, Fortugno T, *et al.* Lead, calcium uptake, and related genetic variants in association with renal cell carcinoma risk in a cohort of male Finnish smokers. *Cancer Epidemiol Biomarkers Prev* 2012; 21: 191-201.
39. Smits KM, Schouten LJ, Hudak E, *et al*. Body mass index and von Hippel-Lindau gene mutations in clear-cell renal cancer: Results of the Netherlands Cohort Study on diet and cancer. *Ann Epidemiol* 2010; 20: 401-4.
40. Sawada N, Inoue M, Sasazuki S, *et al.* Body mass index and subsequent risk of kidney cancer: a prospective cohort study in Japan. *Ann Epidemiol* 2010; 20: 466-72.
41. Andreotti G, Hou L, Beane Freeman LE, *et al.* Body mass index, agricultural pesticide use, and cancer incidence in the Agricultural Health Study cohort. *Cancer Causes Control* 2010; 21: 1759-75.
42. Wilson RT, Wang J, Chinchilli V, *et al*. Fish, vitamin D, and flavonoids in relation to renal cell cancer among smokers. *Am J Epidemiol* 2009; 170: 717-29.
43. Prentice RL, Shaw PA, Bingham SA, *et al.* Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. *Am J Epidemiol* 2009; 169: 977-89.
44. Song YM, Sung J, and Ha M. Obesity and risk of cancer in postmenopausal Korean women. *J Clin Oncol* 2008; 26: 3395-402.
45. Jee SH, Yun JE, Park EJ, **et al.** Body mass index and cancer risk in Korean men and women. *Int J Cancer* 2008; 123: 1892-6.
46. Adams KF, Leitzmann MF, Albanes D, *et al.* Body size and renal cell cancer incidence in a large US cohort study. *Am J Epidemiol* 2008; 168: 268-77.
47. Fujino Y. Anthropometry, development history and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). *Asian Pac J Cancer Prev* 2007; 8 Suppl.: 105-12.
48. Luo J, Margolis KL, Adami HO, *et al.* Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). *Am J Epidemiol* 2007; 166: 752-9.

49. Reeves GK, Pirie K, Beral V, *et al*. Cancer incidence and mortality in relation to body mass *index in the Million Women Study: cohort study. BMJ* 2007; 335: 1134.

50. Samanic C, Chow WH, Gridley G, *et al*. Relation of body mass index to cancer risk in 362,552 Swedish men. *Cancer Causes Control* 2006; 17: 901-9.

51. Pischon T, Lahmann PH, Boeing H, *et al.* Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2006; 118: 728-38.

52. Lukanova A, Bjor O, Kaaks R, *et al*. Body mass index and cancer: results from the Northern Sweden Health and Disease Cohort. *Int JC ancer* 2006; 118: 458-66.

53. Rapp K, Schroeder J, Klenk J, *et al.* Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. *Br J Cancer* 2005; 93: 1062-7.

54. Ali MA, Akhmedkhanov A, Zeleniuch-Jaquotte A, *et al*. Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women. C*ancer Detect Prev 2003;* 27: 116-21.

55. Bergstrom A, Terry P, Lindblad P, *et al.* Physical activity and risk of renal cell cancer. *Int J Cancer* 2001; 92: 155-7.

56. Fraser GE, Phillips RL, and Beeson WL. Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists. *Int J Epidemiol* 1990; 19: 832-8.

57. Whittemore AS, Paffenbarger RS, Jr., Anderson K, *et al.* Early precursors of urogenital cancers in former college men. *J Urol* 1984; 132: 1256-61.

58. Haggstrom C, Rapp K, Stocks T, *et al.* Metabolic factors associated with risk of renal cell carcinoma. *P Lo S One* 2013; 8: e57475.

59. Whitlock G, Lewington S, Sherliker P, *et al.* Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009; 373: 1083-96.

60. Parr CL, Batty GD, Lam TH, *et al.* Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. *Lancet Oncol* 2010; 11: 741-52.

61. Renehan AG, Tyson M, Egger M, *et al.* Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008; 371: 569-78.

62. Ildaphonse G, George PS, and Mathew A. Obesity and kidney cancer risk in men: a meta-analysis (1992-2008). *Asian Pac J Cancer Prev* 2009; 10: 279-86.

63. Mathew A, George PS, and Ildaphonse G. Obesity and kidney cancer risk in women: a meta-analysis (1992-2008). *Asian Pac J Cancer Prev* 2009; 10: 471-8.

64. Hughes LA, Schouten LJ, Goldbohm RA, *et al.* Self-reported clothing size as a proxy measure for body size. *Epidemiology* 2009; 20: 673-6.

65. Abdullah A, Peeters A, de Courten M, *et al.* The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. *Diabetes Res Clin Pract* 2010; 89: 309-19.

66. Hall JE, Brands MW, and Henegar JR. Mechanisms of hypertension and kidney disease in obesity. *Ann N Y Acad Sci* 1999; 892: 91-107.

67. Chow WH, Gridley G, Fraumeni JF, Jr., *et al*. Obesity, hypertension, and the risk of kidney cancer in men. *N Engl J Med* 2000; 343: 1305-11.

68. Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer 2*004; 4: 579-91.

69. Kabat GC, Heo M, Kamensky V, *et al*. Adult height in relation to risk of cancer in a cohort of Canadian women. *Int J Cancer 2013*; 132: 1125-32.

70. Green J, Cairns BJ, Casabonne D, *et al.* Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. *Lancet Oncol* 2011; 12: 785-94.

71. Batty GD, Shipley MJ, Langenberg C, *et al.* Adult height in relation to mortality from 14 cancer sites in men in London (UK): evidence from the original Whitehall study. *Ann Oncol* 2006; 17: 157-66.

72. Whittemore AS, Paffenbarger RS, Jr., Anderson K, *et al.* Early precursors of site-specific cancers in college men and women. *J Natl Cancer Inst* 1985; 74: 43-51.

73. Batty GD, Barzi F, Woodward M, *et al*. Adult height and cancer mortality in Asia: the Asia Pacific Cohort Studies Collaboration. *Ann Oncol* 2010; 21: 646-54.

74. Barker DJ and Thornburg KL. Placental programming of chronic diseases, cancer and lifespan: a review. *Placenta* 2013; 34: 841-5.

75. Rolland-Cachera MF. Rate of growth in early life: a predictor of later health? *Adv Exp Med Biol* 2005; 569: 35-9.

76. Le Roith D, Bondy C, Yakar S, *et al.* The somatomedin hypothesis: 2001. *Endocr Rev* 2001; 22: 53-74.

77. Albanes D and Winick M. Are cell number and cell proliferation risk factors for cancer? *J Natl Cancer Inst* 1988; 80: 772-4.

78. Trichopoulos D and Lipworth L. Is cancer causation simpler than we thought, but more intractable? *Epidemiology* 1995; 6: 347-9.

Appendix – Criteria for grading evidence

(Taken from Chapter 3 of the Second Expert Report [1])

This appendix lists the criteria agreed by the Panel that were necessary to support the judgements shown in the matrices. The grades shown here are 'convincing', 'probable', 'limited – suggestive', 'limited – no conclusion' and 'substantial effect on risk unlikely'. In effect, the criteria define these terms.

CONVINCING (STRONG EVIDENCE)

These criteria are for evidence strong enough to support a judgement of a convincing causal relationship, which justifies goals and recommendations designed to reduce the incidence of cancer. A convincing relationship should be robust enough to be highly unlikely to be modified in the foreseeable future as new evidence accumulates.

All of the following were generally required:

- Evidence from more than one study type.
- Evidence from at least two independent cohort studies.
- No substantial unexplained heterogeneity within or between study types or in different populations relating to the presence or absence of an association, or direction of effect.
- Good quality studies to exclude with confidence the possibility that the observed association results from random or systematic error, including confounding, measurement error and selection bias.
- Presence of a plausible biological gradient ('dose-response') in the association. Such a gradient need not be linear or even in the same direction across the different levels of exposure, so long as this can be explained plausibly.
- Strong and plausible experimental evidence, from either human studies or relevant animal models, that typical human exposures can lead to relevant cancer outcomes.

PROBABLE (STRONG EVIDENCE)

These criteria are for evidence strong enough to support a judgement of a probable causal relationship, which would generally justify goals and recommendations designed to reduce the incidence of cancer.

All the following were generally required:

- Evidence from at least two independent cohort studies or at least five case control studies.
- No substantial unexplained heterogeneity between or within study types in the presence or absence of an association or direction of effect.
- Good quality studies to exclude with confidence the possibility that the observed association results from random or systematic error, including confounding, measurement error and selection bias.
- Evidence for biological plausibility.

LIMITED – SUGGESTIVE

These criteria are for evidence that is too limited to permit a probable or convincing causal judgement but is suggestive of a direction of effect. The evidence may have methodological flaws or be limited in amount, but shows a generally consistent direction of effect. This category is broad and includes associations where the evidence falls only slightly below that required to infer a probably causal association, through to those where the evidence is only marginally strong enough to identify a direction of effect. This judgement almost always does not justify recommendations designed to reduce the incidence of cancer. Any exceptions require special explicit justification.

All of the following were generally required:

- Evidence from at least two independent cohort studies or at least five case control studies.
- The direction of effect is generally consistent, though some unexplained heterogeneity may be present.
- Evidence for biological plausibility.

LIMITED – NO CONCLUSION

Evidence is so limited that no firm conclusion can be made. This category represents an entry level and is intended to allow any exposure for which there are sufficient data to warrant Panel consideration, but where insufficient evidence exists to permit a more definitive grading. This does not necessarily mean a limited quantity of evidence. A body of evidence for a particular exposure might be graded 'limited – no conclusion' for a number of reasons. The evidence might be limited by the amount of evidence in terms of the number of studies available, by inconsistency of direction of effect, by poor quality of studies (for example, lack of adjustment for known confounders) or by any combination of these factors.

When an exposure is graded 'limited – no conclusion', this does not necessarily indicate that the Panel has judged that there is evidence of no relationship. With further good-quality research, any exposure graded in this way might in the future be shown to increase or decrease the risk of cancer. Where there is sufficient evidence to give confidence that an exposure is unlikely to have an effect on cancer risk, this exposure will be judged 'substantial effect on risk unlikely'.

There are also many exposures for which there is such limited evidence that no judgement is possible. In these cases, evidence is recorded in the full CUP SLRs on the World Cancer Research Fund International website (**www.wcrf.org**). However, such evidence is usually not included in the summaries.

SUBSTANTIAL EFFECT ON RISK UNLIKELY (STRONG EVIDENCE)

Evidence is strong enough to support a judgement that a particular food, nutrition or physical activity exposure is unlikely to have a substantial causal relation to a cancer outcome. The evidence should be robust enough to be unlikely to be modified in the foreseeable future as new evidence accumulates.

All of the following were generally required:

- Evidence from more than one study type.
- Evidence from at least two independent cohort studies.
- Summary estimate of effect close to 1.0 for comparison of high and low exposure categories.

- No substantial unexplained heterogeneity within or between study types or in different populations.
- Good quality studies to exclude with confidence the possibility that the absence of an observed association results from random or systematic error, including inadequate power, imprecision or error in exposure measurement, inadequate range of exposure, confounding and selection bias.
- Absence of a demonstrable biological gradient ('dose-response').
- Absence of strong and plausible experimental evidence, either from human studies or relevant animal models, that typical human exposures lead to relevant cancer outcomes.

Factors that might misleadingly imply an absence of effect include imprecision of the exposure assessment, an insufficient range of exposure in the study population and inadequate statistical power. Defects in these and other study design attributes might lead to a false conclusion of no effect.

The presence of a plausible, relevant biological mechanism does not necessarily rule out a judgement of 'substantial effect on risk unlikely'. But the presence of robust evidence from appropriate animal models or in humans that a specific mechanism exists, or that typical exposures can lead to cancer outcomes, argues against such a judgement.

Because of the uncertainty inherent in concluding that an exposure has no effect on risk, the criteria used to judge an exposure 'substantial effect on risk unlikely' are roughly equivalent to the criteria used with at least a 'probable' level of confidence. Conclusions of 'substantial effect on risk unlikely' with a lower confidence than this would not be helpful and could overlap with judgements of 'limited – suggestive' or 'limited – no conclusion'.

SPECIAL UPGRADING FACTORS

These are factors that form part of the assessment of the evidence that, when present, can upgrade the judgement reached. So an exposure that might be deemed a 'limited – suggestive' causal factor in the absence, say, of a biological gradient, might be upgraded to 'probable' in its presence. The application of these factors (listed below) requires judgement, and the way in which these judgements affect the final conclusion in the matrix are stated.

- Presence of a plausible biological gradient ('dose-response') in the association. Such a gradient need not be linear or even in the same direction across the different levels of exposure, so long as it can be explained plausibly.
- A particularly large summary effect size (an odds ratio or relative risk of 2.0 or more, depending on the unit of exposure) after appropriate control for confounders.
- Evidence from randomised trials in humans.
- Evidence from appropriately controlled experiments demonstrating one or more plausible and specific mechanisms actually operating in humans.
- Robust and reproducible evidence from experimental studies in appropriate animal models showing that typical human exposures can lead to relevant cancer outcomes.

NOTES

NOTES

Our Recommendations for Cancer Prevention

Body fatness
Be as lean as possible without becoming underweight

Physical activity
Be physically active for at least 30 minutes every day

Foods and drinks that promote weight gain
Limit consumption of energy-dense foods and avoid sugary drinks

Plant foods
Eat more of a variety of vegetables, fruits, wholegrains and pulses such as beans

Animal foods
Limit consumption of red meats (such as beef, pork and lamb), and avoid processed meats

Alcoholic drinks
If consumed at all, limit alcohol to a maximum of 2 drinks a day for men and 1 drink a day for women

Preservation, processing, preparation
Limit consumption of salt, and avoid mouldy cereals and pulses

Dietary supplements
Don't use supplements to protect against cancer

Breastfeeding
It is best for mothers to breastfeed exclusively for up to six months and then add other liquids and foods

Cancer survivors
After treatment, cancer survivors should follow the recommendations for cancer prevention

World Cancer Research Fund International

World Cancer Research Fund International
Second Floor
22 Bedford Square
London WC1B 3HH
United Kingdom

Tel: +44 (0) 20 7343 4200
Fax: +44 (0) 20 7343 4220
Email: international@wcrf.org

 twitter.com/wcrfint

 facebook.com/wcrfint

Blog wcrf.org/blog

www.wcrf.org

WIRZ9CUPKR